Cytologics

Cytologics operates as a critical supplier in the life sciences research ecosystem, addressing the persistent industry challenge of accessing consistent, high-quality, and ethically-procured human immune cells. The company leverages an FDA-registered donor network, a dedicated cell manufacturing lab, and a focus on fast turnaround to provide researchers with viable, well-characterized specimens. By positioning itself as a partner for academic, biotech, and pharmaceutical R&D, Cytologics enables advancements in cell and gene therapy without developing its own therapeutic pipeline. Its business model is purely service- and product-based, generating revenue from the sale of cellular products and related processing services.

Integrated operational platform for ethical donor sourcing, cell processing, quality control, and logistics for primary human immune cells.

Cytologics competes in the life science research tools market against large, diversified players like STEMCELL Technologies, ATCC, and Lonza, as well as numerous smaller specialty cell providers. Its differentiation is focused on fast turnaround of fresh cells, rigorous post-thaw quality control, and an emphasis on ethical sourcing from an FDA-registered network.